Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease

Orfanoudaki, Eleni; Zacharopoulou, Eirini; Kitsou, Vassiliki; Karmiris, Konstantinos; Theodoropoulou, Anǵeliki; Mantzaris, Gerassimos J.; Tzouvala, Maria; Michopoulos, Spyridon; Zampeli, Evanthia; Michalopoulos, Georgios; Viazis, N.; Liatsos, Christos; Bamias, Giorgos; Koutroubakis, Ioannis Ε.

doi:10.3390/jcm11030641

Cited by 7 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 18 Conflicting data exist in the literature regarding the effect of treatment with biologics, with some studies reporting fewer AEs in IBD patients treated with anti-TNFα, and other showing no correlation. 17 , 20 , 30 , 31 We did not find similar associations in our study. The role of immunosuppressive treatment in AE rate following anti-SARS-Cov-2 vaccination is yet to be elucidated.…”

Section: Discussioncontrasting

confidence: 85%

Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry

Zacharopoulou

Orfanoudaki

Tzouvala

et al. 2022

Inflammatory Bowel Diseases

Self Cite

View full text Add to dashboard Cite

Background Four EMA-approved vaccines against SARS-CoV-2 are currently available. Data regarding antibody responses to initial vaccination regimens in patients with inflammatory bowel diseases (IBD) are limited. Methods We conducted a prospective, controlled, multicenter study in tertiary Greek IBD centers. Participating patients had completed the initial vaccination regimens (1 or 2 doses, depending on the type of COVID-19 vaccine) at least 2 weeks before study enrolment. Anti-S1 IgG antibody levels were measured. Demographic and adverse events data were collected. Results We tested 403 patients (Crohn’s disease, 58.9%; male, 53.4%; median age, 45 years) and 124 healthy controls (HCs). Following full vaccination, 98% of patients seroconverted, with mRNA vaccines inducing higher seroconversion rates than viral vector vaccines (P = .021). In total, IBD patients had lower anti-S1 levels than HCs (P < .001). In the multivariate analysis, viral vector vaccines (P < .001), longer time to antibody testing (P < .001), anti-TNFα treatment (P = .013), and age (P = .016) were independently associated with lower anti-S1 titers. Vedolizumab monotherapy was associated with higher antibody levels than anti-TNFα or anti-interleukin-12/IL-23 monotherapy (P = .023 and P = .032). All anti- SARS-CoV-2 vaccines were safe. Conclusions Patients with IBD have impaired antibody responses to anti-SARS-CoV-2 vaccination, particularly those receiving viral vector vaccines and those on anti-TNFα treatment. Older age also hampers antibody production after vaccination. For those low-response groups, administration of accelerated or prioritized booster vaccination may be considered.

show abstract

Section: Discussioncontrasting

confidence: 85%

Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry

Zacharopoulou

Orfanoudaki

Tzouvala

et al. 2022

Inflammatory Bowel Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

“…The data from the study on Greeks were mainly from case reports [ 31 , 32 , 33 ] that examined sporadic cases of severe/odd reactions to the COVID-19 vaccine; there was a lack of observational studies reporting on reactions to the COVID-19 vaccine and its booster. The rate of serious reactions to the COVID-19 vaccine among Americans was 9.2% in those vaccinated with the first/second dose [ 34 ], 7.6% of first-booster recipients [ 35 ], and 5.1% of second-booster recipients [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Vaccine Booster Hesitancy in Malaysia: A Web-Based Cross-Sectional Study

et al. 2023

View full text Add to dashboard Cite

Vaccination is a key public health strategy that is known to be effective in mitigating the risk of infection and severe disease. However, in the context of the COVID-19 pandemic, the percentage (<50%) of Malaysians who have received a booster for the COVID-19 vaccine has remained stagnant over a year. This study aimed to determine the prevalence of and the factors associated with hesitancy toward the second dose of booster for the COVID-19 vaccine. A web-based cross-sectional study was conducted from August to November 2022. The Oxford Vaccine Hesitancy Scale was used to assess the hesitancy toward the second dose of booster for the COVID-19 vaccine. Simple and multiple factors logistic regressions were used to determine the predictors of hesitancy. A p-value less than 0.05 was considered to be statistically significant. Data from 798 respondents were included in the analysis. The prevalence of hesitancy toward the second booster of the COVID-19 vaccine was 26.7%. The predictors of second-booster hesitancy were older age (AOR = 1.040, 95 CI = 1.022, 1.058), having received the third dose (first booster) because of instruction by the government (AOR = 2.125, 95% CI = 1.380, 3.274), concern about serious long term side effects of the vaccine (AOR = 4.010, 95% CI = 2.218, 7.250), and opinions of close friends and immediate family members that the booster is harmful (AOR = 2.201, 95% CI = 1.280, 3.785). Conversely, factors that appear to reduce vaccine booster hesitancy were acceptance of the third dose due to the high number of cases and the increasing rate of infection (AOR = 0.548, 95% CI = 0.317, 0.947), the belief that the vaccine will decrease the risk of getting the infection (AOR = 0.491, 95% CI = 0.277, 0.870), and opinions of close friends and immediate family members that the booster is helpful (AOR = 0.479, 95% CI = 0.273, 0.840). In conclusion, more than one-fifth of Malaysians were hesitant to take the second booster of the COVID-19 vaccine. This suggests that appropriate steps that increase vaccine acceptance, taking into consideration the findings of the present study, are needed to address this issue and to foster more positive attitudes toward vaccination. The survey was available in three main languages but limited to people with internet access; hence, it would likely be biased toward younger adults and social media users and exclude those with limited or no internet access, in particular older people. Therefore, the results are not representative of the Malaysian population at large and caution should be exercised when interpreting the findings.

show abstract

“…Numerous groups and experts support the importance of adequate vaccination of IBD patients for the prevention of COVID-19, since the existing vaccines appear to be safe for this population and not associated with onset and/or exacerbations of IBD [6] , [7] , [8] . Initial concerns that immunosuppressive treatments might abrogate the development of anti–SARS-COV2 antibodies and impair the protective effect of the available SARS-CoV-2 vaccines in IBD patients, were not further supported by published data.…”

Section: Discussionmentioning

confidence: 99%

The natural history of COVID-19 in vaccinated inflammatory bowel disease patients

Viazis¹,

Drygiannakis

Karmiris

et al. 2023

Digestive and Liver Disease

View full text Add to dashboard Cite

Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease

Cited by 7 publications

References 39 publications

Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry

Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry

COVID-19 Vaccine Booster Hesitancy in Malaysia: A Web-Based Cross-Sectional Study

The natural history of COVID-19 in vaccinated inflammatory bowel disease patients

Contact Info

Product

Resources

About